China's NMPA Approves Iaso Bio, Innovent Biologics' Fucaso in Multiple Myeloma

Chinese regulators approved the first autologous BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma patients.

Related Keywords

China ,Chinese ,Iaso Bio ,Drug Administration ,China National Medical Products Administration ,National Medical Products Administration ,Innovent Biologic ,